CoChat

Addressing Manufacturing Challenges for Commercialization of iPSC-Based Therapies

Dashtban, Mehdi, Panchalingam, Krishna Morgan, Shafa, Mehdi, Ahmadian Baghbaderani, Behnam · 2020 · Methods in Molecular Biology
Cited by 17

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/7651_2020_288

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 34

  1. Rao M (2008) Scalable human ES culture for therapeutic use: propagation, differentiation, genetic modification and regulatory issues. Gene Ther 15(2):82–88. https://doi.org/10.1038/sj.gt.3303061 · DOI
  2. Rao M, Condic ML (2008) Alternative sources of pluripotent stem cells: scientific solutions to an ethical dilemma. Stem Cells Dev 17(1):1–10. https://doi.org/10.1089/scd.2008.0013 · DOI
  3. Chen VC, Couture SM, Ye J, Lin Z, Hua G, Huang HI, Wu J, Hsu D, Carpenter MK, Couture LA (2012) Scalable GMP compliant suspension culture system for human ES cells. Stem Cell Res 8(3):388–402. https://doi.org/10.1016/j.scr.2012.02.001 · DOI
  4. Ellerstrom C, Strehl R, Moya K, Andersson K, Bergh C, Lundin K, Hyllner J, Semb H (2006) Derivation of a xeno-free human embryonic stem cell line. Stem Cells 24(10):2170–2176. https://doi.org/10.1634/stemcells.2006-0130 · DOI · Paper page
  5. Shinde V, Sureshkumar P, Sotiriadou I, Hescheler J, Sachinidis A (2016) Human embryonic and induced pluripotent stem cell based toxicity testing models: future applications in new drug discovery. Curr Med Chem 23(30):3495–3509 · DOI · Paper page
  6. Lee DF, Su J, Kim HS, Chang B, Papatsenko D, Zhao R, Yuan Y, Gingold J, Xia W, Darr H, Mirzayans R, Hung MC, Schaniel C, Lemischka IR (2015) Modeling familial cancer with induced pluripotent stem cells. Cell 161(2):240–254. https://doi.org/10.1016/j.cell.2015.02.045 · DOI · Paper page
  7. Ilic D, Devito L, Miere C, Codognotto S (2015) Human embryonic and induced pluripotent stem cells in clinical trials. Br Med Bull 116:19–27. https://doi.org/10.1093/bmb/ldv045 · DOI
  8. Guhr A, Kobold S, Seltmann S, Seiler Wulczyn AEM, Kurtz A, Loser P (2018) Recent trends in research with human pluripotent stem cells: impact of research and use of cell lines in experimental research and clinical trials. Stem Cell Reports 11(2):485–496. https://doi.org/10.1016/j.stemcr.2018.06.012 · DOI · Paper page
  9. Takahashi J (2017) Strategies for bringing stem cell-derived dopamine neurons to the clinic: the Kyoto trial. Prog Brain Res 230:213–226. https://doi.org/10.1016/bs.pbr.2016.11.004 · DOI
  10. Hu S, Yang J, Shangguan J, Eresen A, Li Y, Ma Q, Yaghmai V, Velichko Y, Hu C, Zhang Z (2019) Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a Kras(LSL-G12D) p53(LSL-R172H) Pdx1-Cre mouse model. Am J Cancer Res 9(8):1757–1765
  11. Shafa M, Yang F, Fellner T, Rao MS, Baghbaderani BA (2018) Human-induced pluripotent stem cells manufactured using a current good manufacturing practice-compliant process differentiate into clinically relevant cells from three germ layers. Front Med (Lausanne) 5:69. https://doi.org/10.3389/fmed.2018.00069 · DOI · Paper page
  12. Chou BK, Mali P, Huang X, Ye Z, Dowey SN, Resar LM, Zou C, Zhang YA, Tong J, Cheng L (2011) Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res 21(3):518–529. https://doi.org/10.1038/cr.2011.12 · DOI · Paper page
  13. Shafa M, Panchalingam KM, Walsh T, Richardson T, Baghbaderani BA (2019) Computational fluid dynamics modeling, a novel, and effective approach for developing scalable cell therapy manufacturing processes. Biotechnol Bioeng 116(12):3228–3241. https://doi.org/10.1002/bit.27159 · DOI
  14. Baghbaderani BA, Syama A, Sivapatham R, Pei Y, Mukherjee O, Fellner T, Zeng X, Rao MS (2016) Detailed characterization of human induced pluripotent stem cells manufactured for therapeutic applications. Stem Cell Rev Rep 12(4):394–420. https://doi.org/10.1007/s12015-016-9662-8 · DOI · Paper page
  15. Shafa M, Walsh T, Panchalingam KM, Richardson T, Menendez L, Tian X, Suresh Babu S, Dadgar S, Beller J, Yang F, Baghbaderani BA (2019) Long-term stability and differentiation potential of cryopreserved cGMP-compliant human induced pluripotent stem cells. Int J Mol Sci 21(1). https://doi.org/10.3390/ijms21010108 · DOI
  16. Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee MJ, Ji H, Ehrlich LI, Yabuuchi A, Takeuchi A, Cunniff KC, Hongguang H, McKinney-Freeman S, Naveiras O, Yoon TJ, Irizarry RA, Jung N, Seita J, Hanna J, Murakami P, Jaenisch R, Weissleder R, Orkin SH, Weissman IL, Feinberg AP, Daley GQ (2010) Epigenetic memory in induced pluripotent stem cells. Nature 467(7313):285–290. https://doi.org/10.1038/nature09342 · DOI · Paper page
  17. Rao M, Ahrlund-Richter L, Kaufman DS (2012) Concise review: cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities. Stem Cells 30(1):55–60. https://doi.org/10.1002/stem.770 · DOI · Paper page
  18. Gonzalez M, Martin-Ruiz I, Jimenez S, Pirone L, Barrio R, Sutherland JD (2011) Generation of stable Drosophila cell lines using multicistronic vectors. Sci Rep 1:75. https://doi.org/10.1038/srep00075 · DOI · Paper page
  19. Ichida JK, Blanchard J, Lam K, Son EY, Chung JE, Egli D, Loh KM, Carter AC, Di Giorgio FP, Koszka K, Huangfu D, Akutsu H, Liu DR, Rubin LL, Eggan K (2009) A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 5(5):491–503. https://doi.org/10.1016/j.stem.2009.09.012 · DOI · Paper page
  20. Lyssiotis CA, Foreman RK, Staerk J, Garcia M, Mathur D, Markoulaki S, Hanna J, Lairson LL, Charette BD, Bouchez LC, Bollong M, Kunick C, Brinker A, Cho CY, Schultz PG, Jaenisch R (2009) Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A 106(22):8912–8917. https://doi.org/10.1073/pnas.0903860106 · DOI · Paper page
  21. Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T, Hao E, Hayek A, Deng H, Ding S (2009) Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 4(1):16–19. https://doi.org/10.1016/j.stem.2008.11.014 · DOI · Paper page
  22. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA (2008) Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 26(7):795–797. https://doi.org/10.1038/nbt1418 · DOI · Paper page
  23. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S (2011) A more efficient method to generate integration-free human iPS cells. Nat Methods 8(5):409–412. https://doi.org/10.1038/nmeth.1591 · DOI · Paper page
  24. Goh PA, Caxaria S, Casper C, Rosales C, Warner TT, Coffey PJ, Nathwani AC (2013) A systematic evaluation of integration free reprogramming methods for deriving clinically relevant patient specific induced pluripotent stem (iPS) cells. PLoS One 8(11):e81622. https://doi.org/10.1371/journal.pone.0081622 · DOI · Paper page
  25. Nie Y, Walsh P, Clarke DL, Rowley JA, Fellner T (2014) Scalable passaging of adherent human pluripotent stem cells. PLoS One 9(1):e88012. https://doi.org/10.1371/journal.pone.0088012 · DOI · Paper page
  26. Stacey GN, Crook JM, Hei D, Ludwig T (2013) Banking human induced pluripotent stem cells: lessons learned from embryonic stem cells? Cell Stem Cell 13(4):385–388. https://doi.org/10.1016/j.stem.2013.09.007 · DOI
  27. ICH (2005) Q2 (R1), Validation of analytical procedures: text and methodology, ICH harmonised tripartite guideline. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use, Chicago, USA
  28. Mummery CL, Zhang J, Ng ES, Elliott DA, Elefanty AG, Kamp TJ (2012) Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res 111(3):344–358. https://doi.org/10.1161/CIRCRESAHA.110.227512 · DOI · Paper page
  29. Krawetz R, Taiani JT, Liu S, Meng G, Li X, Kallos MS, Rancourt DE (2010) Large-scale expansion of pluripotent human embryonic stem cells in stirred-suspension bioreactors. Tissue Eng Part C Methods 16(4):573–582. https://doi.org/10.1089/ten.TEC.2009.0228 · DOI · Paper page
  30. Zweigerdt R, Olmer R, Singh H, Haverich A, Martin U (2011) Scalable expansion of human pluripotent stem cells in suspension culture. Nat Protoc 6(5):689–700. https://doi.org/10.1038/nprot.2011.318 · DOI · Paper page
  31. Butler M (2003) Animal cell culture and technology. Taylor & Francis, London. https://doi.org/10.4324/9780203427835 · DOI
  32. Aunins JG, Woodson BA Jr, Hale TK, Wang DI (1989) Effects of paddle impeller geometry on power input and mass transfer in small-scale animal cell culture vessels. Biotechnol Bioeng 34(9):1127–1132. https://doi.org/10.1002/bit.260340902 · DOI
  33. Shuler ML, Kargi F (2002) Bioprocess engineering: basic concepts, 2nd edn. Prentice Hall PTR, Upper Saddle River
  34. Borys BS, Le A, Roberts EL, Dang T, Rohani L, Hsu CY, Wyma AA, Rancourt DE, Gates ID, Kallos MS (2019) Using computational fluid dynamics (CFD) modeling to understand murine embryonic stem cell aggregate size and pluripotency distributions in stirred suspension bioreactors. J Biotechnol 304:16–27. https://doi.org/10.1016/j.jbiotec.2019.08.002 · DOI

Cited by

Metadata

Authors
Dashtban, M., Panchalingam, K. M., Shafa, M., & Ahmadian Baghbaderani, B.
Venue
Methods in Molecular Biology
Publisher
Springer US
Published
2020
Pages
179-198
ISSN
  • 1064-3745
  • 1940-6029
Cited by
17
References
9
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.